AbbVie has agreed to acquire Apogee Therapeutics in a $10.9 billion deal, strengthening its position in the fast-growing immunology market.
The acquisition brings zumilokibart, a promising late-stage treatment for eczema (atopic dermatitis), into AbbVie’s portfolio. Industry experts believe the therapy could offer a competitive alternative to existing treatments with the potential for less frequent dosing and improved patient convenience.
This move highlights the continued race among pharmaceutical companies to develop innovative therapies for chronic inflammatory diseases and improve outcomes for millions of patients worldwide.
What impact do you think this acquisition will have on the future of eczema treatment?
Click here to read the entire article.
